Monitor for development of EGFR T790M drug-resistant mutation in patients administered tyrosine kinase inhibitor (TKI) therapy for EGFR-mutant non-small cell lung cancer. Monitor response to therapy and disease progression in patients treated with EGFR T790M-specific TKIs.
Polymerase Chain Reaction
Whole blood in two 10 mL Cell-Free DNA (cfDNA) BCT Tubes (ARUP Supply #52358) available online through eSupply or contacting ARUP Client Services at (800) 522-2787. Also acceptable: CSF collected in a sterile container.
Whole Blood: Transport 20 mL whole blood. (Min: 16 mL)
CSF: Transport 4 mL CSF. (Min: 4 mL)
FFPE tissue. Whole Blood collected in non-cfDNA BCT tubes.
Whole Blood: Ambient: 5 days; Refrigerated: 5 days; Frozen: Unacceptable
CSF: Ambient: Unacceptable; Refrigerated: 5 days; Frozen: Unacceptable
Refer to report.
Laboratory Developed Test (LDT)
|Component Test Code*||Component Chart Name||LOINC|
|2012869||EGFR T790M Result||55769-4|